Cwm LLC Sells 91 Shares of Repligen Co. (NASDAQ:RGEN)

Cwm LLC decreased its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 23.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 301 shares of the biotechnology company’s stock after selling 91 shares during the period. Cwm LLC’s holdings in Repligen were worth $54,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in RGEN. Artisan Partners Limited Partnership lifted its stake in Repligen by 11.3% in the third quarter. Artisan Partners Limited Partnership now owns 1,556,873 shares of the biotechnology company’s stock valued at $247,558,000 after buying an additional 157,807 shares during the period. Wellington Management Group LLP boosted its stake in Repligen by 2.1% during the 3rd quarter. Wellington Management Group LLP now owns 1,396,610 shares of the biotechnology company’s stock worth $222,075,000 after acquiring an additional 29,215 shares during the last quarter. Conestoga Capital Advisors LLC grew its holdings in Repligen by 0.4% during the fourth quarter. Conestoga Capital Advisors LLC now owns 709,738 shares of the biotechnology company’s stock valued at $127,611,000 after purchasing an additional 2,590 shares during the period. Parnassus Investments LLC bought a new stake in Repligen in the third quarter valued at approximately $87,475,000. Finally, Northern Trust Corp raised its holdings in Repligen by 2.4% in the third quarter. Northern Trust Corp now owns 471,919 shares of the biotechnology company’s stock worth $75,040,000 after purchasing an additional 11,204 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Activity at Repligen

In related news, VP Ralf Kuriyel sold 3,517 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the completion of the transaction, the vice president now directly owns 24,260 shares of the company’s stock, valued at $4,699,889.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Repligen news, Director Karen A. Dawes sold 1,000 shares of the company’s stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total transaction of $193,350.00. Following the sale, the director now directly owns 87,367 shares of the company’s stock, valued at $16,892,409.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Ralf Kuriyel sold 3,517 shares of the stock in a transaction on Monday, March 11th. The shares were sold at an average price of $193.73, for a total transaction of $681,348.41. Following the completion of the sale, the vice president now owns 24,260 shares of the company’s stock, valued at approximately $4,699,889.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 25,597 shares of company stock valued at $5,039,532. 1.20% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. KeyCorp upped their price objective on shares of Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. JPMorgan Chase & Co. cut their price objective on Repligen from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday, May 2nd. Finally, Stifel Nicolaus increased their target price on Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $197.75.

Repligen Trading Down 1.3 %

NASDAQ:RGEN opened at $165.50 on Thursday. The company has a quick ratio of 5.24, a current ratio of 6.35 and a debt-to-equity ratio of 0.26. Repligen Co. has a twelve month low of $110.45 and a twelve month high of $211.13. The company has a market cap of $9.25 billion, a P/E ratio of 662.00, a price-to-earnings-growth ratio of 5.58 and a beta of 1.03. The business has a 50 day moving average price of $179.23 and a two-hundred day moving average price of $174.56.

Repligen (NASDAQ:RGEN) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.01). Repligen had a return on equity of 3.95% and a net margin of 2.44%. The business had revenue of $151.31 million for the quarter, compared to analyst estimates of $150.06 million. During the same quarter in the previous year, the company posted $0.64 EPS. The business’s revenue for the quarter was down 17.1% compared to the same quarter last year. As a group, analysts expect that Repligen Co. will post 1.46 EPS for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.